NEDA

Ocrevus Benefited RRMS Patients Who Responded Poorly to DMTs

Most relapsing-remitting multiple sclerosis (RRMS) patients switching to Ocrevus (ocrelizumab) following suboptimal responses to other disease-modifying therapies (DMTs) show no evidence of disease activity, according to final two-year data from the European-based CASTING Phase 3b trial. These clinical benefits, which entail no relapses or disease progression and no…

Early High-efficacy Therapies May Be Better to Eliminate MS Activity

Using high-efficacy therapies as a first treatment for multiple sclerosis (MS) patients significantly increases the likelihood of having no evidence of disease activity after one and two years, compared to using moderately effective therapies, according to a real-world study of Norwegian patients. However, with each additional attempted treatment, the…

Tysabri Superior to Gilenya at Easing Activity in RRMS, Study Reports

Treatment with Tysabri (natalizumab) was more effective thanĀ Gilenya (fingolimod) in helping people with relapsingā€“remitting multiple sclerosis (RRMS) achieve no evidence of disease activity, a head-to-head study suggested. The study, “BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS,” was…

#MSVirtual2020 – Pediatric MS Patients May Do Best on Intravenous DMTs, Study Finds

Most children and adolescents with pediatric-onset multiple sclerosis (POMS), especially those treated intravenously with a disease-modifying therapyĀ (DMT), achieve no evidence of disease activity within two years of diagnosis, according to a real-life study from the U.S. Patients whose DMTs are infused into a vein (intravenous treatment) areĀ more likely…

#MSVirtual2020 ā€” No Evidence of Disease Activity Seen in Most RRMS Patients After Switching to Ocrevus, Data Show

Switching to Genentechā€™s OcrevusĀ (ocrelizumab) following suboptimal treatment responses significantly lessens symptoms and leads to high rates of no evidence of disease activity in people withĀ relapsing-remitting multiple sclerosisĀ (RRMS), according to data from a Phase 3b clinical trial. That finding, as well as data about patients’ adherence and…

Tysabri Treatment Leads to Disease Activity-free Status in Patients with Pediatric-onset MS

Early treatment with Tysabri (natalizumab) of patients with aggressive pediatric-onset multiple sclerosis is highly effective at achieving disease activity-free status and preventing cognitive decline, a new study shows. The study, ā€œNo evidence of disease activity including cognition (NEDA-3 plus) in naĆÆve pediatric multiple sclerosis patients treated with natalizumab,ā€…

#ACTRIMS2019 – No Evidence of Disease Activity Seen in POMS Adolescents Taking Rituximab, Small Study Shows

Data supporting the off-label use of rituximab in adolescents with pediatric-onset multiple sclerosis (POMS) was presented atĀ the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2019. The session, titledĀ ā€œNo Evidence of Disease Activity in the Majority of Pediatric-Onset Multiple Sclerosis Patients Receiving Rituximab,ā€…

Ocrevus’ Journey from Defiant Idea to Game-Changing Treatment

Twenty years ago, the idea that B-cell depletion could treat multiple sclerosisĀ would have been greeted with a hearty laughĀ byĀ any well-respected neurologist or MS researcher ā€” or perhapsĀ a scoff. But times change and research advances. Today, a medicine that gets rid of certain B-cells may beĀ the most powerful drug yetĀ developed against…

#ACTRIMS2017 – Ocrevus Significantly Decreases Disease Activity in MS Patients, Study Shows

Ocrevus (ocrelizumab), an investigational monoclonal antibody, significantly decreases disease activity in patients with multiple sclerosis (MS), and is associated with a higher proportion of patients reaching no evidence of disease activity (NEDA), according to a new analysis. The study,Ā ā€œNEDA analysis by epoch in patients with relapsing multiple…

#ECTRIMS2016 – Treatment for Relapsing MS, Ozanimod, Shows Efficacy in 2-Year Extension of Phase 2 Study

Results from the extension period of aĀ Phase 2 trial,Ā assessingĀ ozanimod as a potential treatment for relapsing-remitting multiple sclerosis, showed that the drug can effectively and safely improve clinical measures of RRMS after two years of treatment. The announcement was made by Celgene International SĆ rl, a subsidiary of Celgene Corporation,…

#ECTRIMS2016 – Biogen and AbbVie Present New Positive Data on Zinbryta to Treat Relapsing MS

BiogenĀ andĀ AbbVieĀ presented positive new post-hoc analysis from the pivotal DECIDE clinical trial, whichĀ showed that a significantly larger number of relapsing multiple sclerosis (RMS) patients treated with Zinbryta (daclizumab) hadĀ no evidence of disease activity (NEDA)Ā compared to thoseĀ treated with Avonex (interferon beta-1a).Ā The data wereĀ given at the recentĀ 32nd Congress of the European…

#ECTRIMS2016 – Stem Cell Transplantation Shows High Efficiency

A high fraction of patients with multiple sclerosis (MS) who underwent a transplant with their own bone marrow stem cells after immunosupression therapy, show no signs of disease activity after treatment, according to a new study. The results were presented inĀ a talk, ā€œClinical experience in aggressive multiple sclerosis treatment with…

#ECTRIMS2016 – New Data Show Ocrevus Effective in Treating Primary and Relapsing MS

Positive new dataĀ from Phase 3 clinical trials assessingĀ Ocrevus (ocrelizumab) as a treatment for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) were recently announced by Roche, the company responsible for marketing and developing this investigationalĀ therapy. The results are being presented at the 32nd Congress of the…

#CMSC16 – STRIVE Study Confirms Tysabri (Natalizumab) Safety in Early Relapsing-Remitting MS

Results from the STRIVE study support the safety of natalizumabĀ (Tysabri) as a therapy for multiple sclerosis (MS) patients. The study, “Natalizumab in Anti-JC Virus Seronegative Patients with Early Relapsing-Remitting Multiple Sclerosis: Interim Results from the STRIVE Study,”Ā was recentlyĀ presented at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis…